Pulsenmore Ltd. (PLSM)
NASDAQ: PLSM · Real-Time Price · USD
3.605
+0.115 (3.30%)
At close: Apr 14, 2026, 4:00 PM EDT
3.620
+0.015 (0.42%)
After-hours: Apr 14, 2026, 4:54 PM EDT
Pulsenmore Revenue
In the year 2025, Pulsenmore had annual revenue of 40.02M ILS with 314.28% growth. Pulsenmore had revenue of 36.03M in the half year ending December 31, 2025, with 858.62% growth.
Revenue (ttm)
40.02M ILS
Revenue Growth
+314.28%
P/S Ratio
1.84
Revenue / Employee
563,718 ILS
Employees
71
Market Cap
23.10M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.02M | 30.36M | 314.28% |
| Dec 31, 2024 | 9.66M | 3.47M | 56.12% |
| Dec 31, 2023 | 6.19M | -4.63M | -42.78% |
| Dec 31, 2022 | 10.81M | 9.24M | 585.30% |
| Dec 31, 2021 | 1.58M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TELA Bio | 80.28M |
| IRIDEX | 52.68M |
| Myomo | 40.93M |
| Cytosorbents | 37.06M |
| Lifeward | 22.03M |
| Vivos Therapeutics | 17.32M |
| IceCure Medical | 3.38M |
| VolitionRx | 1.73M |
PLSM News
- 15 days ago - Pulsenmore Announces Full Year 2025 Financial Results and Webcast - PRNewsWire
- 20 days ago - Pulsenmore Announces Full Year 2025 Earnings Conference Call - PRNewsWire
- 2 months ago - Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PRNewsWire
- 2 months ago - Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center - PRNewsWire
- 2 months ago - Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation - PRNewsWire
- 2 months ago - Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S. - PRNewsWire